In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here. Patients with ...

A few years earlier I'd helped show that a phosphatidylinositol (PI) kinase activity copurified with various oncoprotein tyrosine kinases, and that this association was critical for the ability of ...

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer ...

We have been comparing signaling pathways activated in ET cell lines ... Serum also activates PI3 kinase-dependent PKB/AKT, involved in cell survival, and induces high levels of cyclin D1/D2 ...

Although inhibitors targeting elements of the PI3K/AKT/mTOR pathway are promising approaches ... provide strong rationale for testing mTOR kinase inhibitors such as MLN0128 with BCR-ABL TKIs ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K ... RAF kinase-driven ERK activation. The combination of Hsp90 inhibitors with RAF or MEK ...

"Aspirin 160 mg reduced recurrence by more than 50% in colorectal cancer patients with tumors harboring mutations in the PI3 kinase pathway," said Martling. "This is the first trial to show that ...